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Abstract 
Increasing numbers of adults, particularly college students, are misusing prescription 
stimulants primarily for cognitive/academic enhancement, so it is critical to explore 
whether empirical findings support neurocognitive benefits of prescription stimulants. 
Previous meta-analytic studies have supported small benefits from prescription stimulants 
for the cognitive domains of inhibitory control and memory; however, no meta-analytic 
studies have examined the effects on processing speed or the potential impairment on 
other domains of cognition, including planning, decision-making, and cognitive 
perseveration. Therefore, the present study conducted a meta-analysis of the available 
literature examining the effects of prescription stimulants on specific measures of 
processing speed, planning, decision-making, and cognitive perseveration among healthy 
adult populations. The meta-analysis results indicated a positive influence of prescription 
stimulant medication on processing speed accuracy, with an overall mean effect size of g 
= 0.282 (95% CI 0.077, 0.488; n = 345). Neither improvements nor impairments were 
revealed for planning time, planning accuracy, advantageous decision-making, or 
cognitive perseveration; however findings are limited by the small number of studies 
examining these outcomes. Findings support that prescription stimulant medication may 
indeed act as a neurocognitive enhancer for accuracy measures of processing speed 
without impeding other areas of cognition. Considering that adults are already engaging 
in illegal use of prescription stimulants for academic enhancement, as well as the 
potential for stimulant misuse to have serious side effects, the establishment of public 
policies informed by interdisciplinary research surrounding this issue, whether restrictive 
or liberal, is of critical importance. 
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Public Health Significance: 
Misuse of prescription stimulants, which hold a high abuse potential, is a growing 
problem among student and non-student adults for enhancement of academic functioning 
and work productivity. By investigating the cognitive effects of prescription stimulants, 
the present meta-analytic study informs potential interventions and policy development 
surrounding prescription stimulant misuse and diversion.  
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Introduction 
The efficacy of prescription stimulant medications for the reduction of Attention-
Deficit/Hyperactivity Disorder (ADHD) symptomatology among adults and children has 
been well documented through clinical trials and meta-analyses (Faraone, 2012; Faraone 
& Biederman, 2002; Faraone & Buitelaar, 2010; Faraone and Glatt, 2010). Prescription 
stimulant misuse for cognitive enhancement, as opposed to ADHD symptom 
management, is a growing problem among adults and college students with and without 
ADHD (Benson, Flory, Humphreys, & Lee, 2015; Weyandt et al., 2013; Weyandt et al., 
2014). College students consistently report enhancing academics as their primary 
motivation for misusing stimulant medication (Benson et al., 2015; Weyandt et al., 2009; 
Weyandt et al., 2013), and adults with ADHD have indicated productivity as a motivation 
for stimulant misuse (Novak, Kroutil, Williams, & Van Brunt 2007). Although the 
widespread misuse of prescription stimulants for cognitive enhancement highlights the 
need for public policy addressing this issue, a number of questions remain about how best 
to approach such policy. Policy development requires in-depth understanding of a) the 
ethical and legal implications associated with prescription stimulant misuse, b) the 
cognitive behavioral effects of these medications in populations with and without ADHD, 
c) the underlying pharmacological mechanisms of these effects, and d) potential genetic 
and neurodevelopmental variation across cognitive and behavioral effects. Although it is 
beyond the scope of the present study to answer all of these questions, by elucidating the 
potential effects of prescription stimulant medications for particular domains of cognitive 
enhancement, we hope to contribute to an interdisciplinary dialogue spanning behavioral, 
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cognitive, and developmental psychology, as well as clinical neuroscience, behavior 
genetics, and pharmacology in order to help inform public policy.  
Two previous reviews have assessed the effect of prescription stimulants on 
cognition in adults with and without ADHD, concluding that the effects of stimulant 
medications on cognitive enhancement vary according to population and task (Advokat, 
2010; Smith & Farah, 2011). These reviews, however, relied on studies that were 
underpowered and varied in design, potentially impeding comparisons across studies. 
Indeed, Smith and Farah (2011) stated that although larger clinical studies assessing the 
cognitive effects of stimulants are warranted, such studies are unlikely to be funded given 
“cognitive enhancement falls between the two stools of research funding” (i.e., disease-
oriented and pharmaceutical funders) (p. 736). In their meta-analysis examining 
prescription stimulant efficacy for ADHD symptoms, Faraone, Biederman, Spencer, and 
Aleardi (2006) reported that comparing effect sizes and results across prescription 
stimulant studies without using statistical techniques to account for study differences 
(e.g., meta-analysis) would result in biased conclusions. Therefore, a meta-analysis 
examining the efficacy of prescription stimulant medications for cognitive enhancement 
in adults, accounting for medication type, medication dose, participant demographics and 
study design, would greatly contribute to the existing literature.  
One meta-analytic study (Ilieva, Hook, & Farah, 2015) has explored the effects of 
prescription stimulant medication on cognition among adults. Findings from this study 
supported small but significant effects of methylphenidate and amphetamine on working 
memory (g = 0.13), episodic memory (g = 0.20) and inhibitory control (g = 0.20), and 
moderate effects on delayed memory (g = 0.45). The researchers speculated that larger 
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effects may be found among other domains of cognition related to learning (e.g., 
processing speed). An additional question that has been raised in the literature (Advokat, 
2010; Ilieva, Boland, & Farah, 2013; Smith & Farah, 2011; Weyandt et al., 2013; 
Weyandt et al., 2014) queries that even if positive benefits are associated with 
prescription stimulant use in some areas of cognition, could these stimulants also be 
associated with impairments of other components of cognition such as planning, 
decision-making and perseveration?  
To date, no meta-analyses have been conducted concerning the effects of 
prescription stimulant medication on processing speed accuracy, planning time and 
accuracy, advantageous decision-making, or cognitive perseveration. Findings from such 
a study will provide important implications for the use and misuse of prescription 
stimulants as a “smart pill” (Smith & Farah, 2011, p. 717) for adults seeking to enhance 
their cognitive functioning and college students hoping to improve their academic 
outcomes. Therefore, the present meta-analytic study examined whether prescription 
stimulants play a role in these specific behaviors of cognition among healthy adults. 
These particular cognitive behaviors were selected because a) to date, no meta-analytic 
studies have examined the effects of prescription stimulants on these cognitive behaviors; 
b) these particular cognitive behaviors will proffer important implications for academic 
enhancement; and c) a pilot search of the literature indicated these areas have been 
adequately studied across neuropsychological research.  
Previous research supports the potential for prescription stimulants to benefit 
processing speed and impede cognitive flexibility; however, the potential for positive or 
negative effects from stimulants on planning and decision-making remains less clear. 
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Processing speed has been described to rely on cognitive processes that involve attention 
and response speed (Lezak, Howieson, Bigler, & Tranel, 2012) and previous research has 
supported prescription stimulant benefits to these areas (Riccio, Waldrop, Reynolds, & 
Lowe, 2001; Schlösser et al., 2009). Further, an increase in error rates on tests of 
cognitive flexibility and set-shifting has been found to associate with prescription 
stimulants (Advokat, 2010; Dyme, Sahakian, Golinko, & Rabe, 1982; Rogers et al., 
1999). Studies examining the effects of prescription stimulants on tasks of decision-
making and planning, however, have mainly reported null effects (Agay, Yechiam, 
Carmel, & Levkovitz, 2010; Agay, Yechiam, Carmel, & Levkovitz, 2014; Elliott et al., 
1997; Linssen,Sambeth, Vuurman, & Riedel , 2012; Turner et al., 2003). Considering that 
both planning and decision-making have been described to involve working memory, 
impulse control and sustained attention (Lezak et al., 2012), and previous research has 
demonstrated that prescription stimulants may result in small boosts in these areas of 
cognition (Ilieva et al., 2015; Koelega, 1993; Riccio et al., 2001), it is possible that 
prescription stimulants will also enhance planning and decision-making.  Therefore, the 
primary hypothesis of the present study is that among healthy adults without ADHD, 
prescription stimulant medications will enhance performance on measures of processing 
speed accuracy, planning time and accuracy, and advantageous decision-making, and 
impair performance on measures of cognitive perseveration.  
Methods 
Literature search  
The systematic search and retrieval process was conducted according to Lipsey 
and Wilson’s (2001) guide for meta-analysis, the Preferred Reporting Items for 
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Systematic Reviews and Meta-Analyses (PRISMA) 27-item checklist (Liberati et al., 
2009; Moher, Liberati, Tetzlaff, & Altman, 2009), and Okoli and Schabram’s (2010) 
eight-step guide to systematic literature reviews. The study attempted to identify and 
retrieve all empirical studies that examined amphetamine or methylphenidate effects on 
processing speed, planning, decision-making and cognitive perseveration conducted at 
any time. The final search and retrieval process was conducted in January 2016 and 
included a comprehensive search of PsycINFO and PubMed. A combination of the 
following keyterms were used: “Prescription stimulant”, amphetamine, Adderall, 
methylphenidate, Ritalin, or Concerta, and  “processing speed”, “psychomotor 
performance”, planning, “decision making”, “cognitive flexibility”, “Digit Symbol 
Substitution Task”, “Iowa Gambling Task”, “Spatial Planning Task”, “Set Shift 
Task”, or “Wisconsin Card Sorting Task”. Studies were also searched within a larger 
pilot study that investigated the effects of prescription stimulants and prostimulants on 
multiple domains of cognition, as well as the following review articles: Advokat, (2010), 
Linssen, Sambeth, Vuurman, and Riedel (2014), Smith and Farah, (2011), and Repantis, 
Schlattmann, Laisney, and Heuser, (2010). Titles, abstracts, and full articles were 
examined to assess if studies met eligibility criteria, described in the following section.  
Study Selection 
Studies were selected for review based on the following criteria: 
A. The study investigated the effects of oral ingestion of amphetamine or 
methylphenidate on processing speed accuracy, planning time, planning 
accuracy, advantageous decision-making, or cognitive perseveration using the 
Digit Symbol Substitution Test (DSST), the Iowa Gambling Task (IGT), the 
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Tower of London (TOL) or New Tower of London (NTOL) Tasks, the 
Wisconsin Card Sorting Task (WCST), or the Intra-Extra Dimensional Set-
shift Task (IDED); if the study investigated additional drugs or measures, only 
data involving the stimulants listed previously and placebo were included.  
B. The study was published in English. 
C. The study used a double blind placebo-controlled design. 
D. The sample included human subjects only, at least 18 years of age; if the study 
included special groups, only data involving healthy controls were included. 
E. The sample size was greater than one; single case studies were excluded. 
F. The procedure did not limit sleep for participants; studies investigating sleep 
deprivation or studies that deprived participants of sleep were excluded. 
G. Studies that used drug discrimination learning procedures, i.e., teaching 
participants to discriminate between drugs or doses of drugs, were excluded in 
order to minimize confounds associated with these learning tasks. 
Data extraction 
Once all studies were identified and retrieved, data were extracted and coded 
independently by two researchers according to a standardized coding manual. To measure 
coder consistency, we calculated percent agreement (94.07%) based on established 
guidelines (Lipsey & Wilson, 2001; Yeaton & Wortman, 1993) and disagreements were 
resolved by discussion and consensus between coders. A comprehensive coding system 
included basic descriptive statistics (sample size, reported effect size statistics, effect 
direction and raw data to recalculate effect size), sample descriptors, study design and 
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study, stimulant medication descriptors, dependent constructs and measures of cognition, 
and the following moderators:  
(1) Stimulant type (methylphenidate vs. amphetamine): Differences between 
methylphenidate (MPH) and amphetamine (AMP) were examined to 
determine if type of stimulant impacted cognitive neuroenhancement. 
(2) Dose (low vs. high): We examined the influence of dose level on stimulants 
for neurocognitive enhancement. Doses coded as “high” included the 
following: ≥ 20-mg (AMP), ≥ 40-mg (MPH). “Low” doses were those that fell 
below this convention. When studies reported dose in units of mg/kg, doses 
were multiplied by the global average adult weight of 62-kg (Walpole et al., 
2012) and then coded accordingly. One study (Elliott et al., 1997) only 
reported the collapsed findings from 20-mg (n = 8) and 40-mg (n = 20) of 
MPH because the researchers did not find significant differences between the 
doses. Considering the majority of participants received the highest dose, we 
coded effect sizes as “high.” 
(3) Sex Distribution: Percent female was coded as an estimate of sex distribution. 
(4) Age of Sample: Mean age and age range were coded to determine the 
influence of participant age on prescription stimulant neuroenhancement. 
(5) Study Design (crossover vs. parallel): Studies were coded as using either a 
crossover or within-subjects design or a parallel or between-subjects design. 
(6) Inclusion of Non-Behavioral Measures (yes vs. no): For an additional 
assessment of publication bias, we followed a format similar to Ilieva et al. 
(2015) and differentiated studies that examined prescription stimulant effects 
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on behavioral tasks only and studies that examined prescription stimulant 
effects on behavioral tasks to better understand neurological or physiological 
outcomes. Studies that conducted cognitive assessments in conjunction with 
neurological (e.g., functional Magnetic Resonance Imaging [fMRI], Event 
Related Potentials [ERP]) or physiological (e.g., electroencephalogram 
[EEG], electrocardiogram [EKG]) assessments were coded in order to account 
for any influence of non-behavioral measures. Studies that utilized biological 
assessments (e.g., blood samples, saliva samples, blood pressure) were not 
coded in this category. 
(7) Timing of Dose Activation (during, prior, vs. after task): Timing of dose 
activation was coded as occurring during learning processes, prior to learning 
process, or after learning processes according to the medication type used in 
each study. Studies utilizing pharmacokinetic data have indicated that plasma 
levels peak after oral ingestion of short-acting amphetamine between 2-3 
hours (Angrist, Corwin, Bartlett, & Cooper, 1987; Wachtel, ElSohly, Ross, 
Ambre, & de Wit, 2002) and short-acting methylphenidate between 1-2 hours 
(Kimko, Cross, & Abernethy, 1999; Volkow et al. 1998). Therefore, doses 
administered within these time windows for each medication were coded as 
occurring “during learning,” doses administered prior were coded as occurring 
“prior to learning,” and doses administered following were coded as occurring 
“after learning.” 
Outcome performance measures and cognitive domains 
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Dependent performance measures and constructs were coded based on methods 
used by previous research and on theoretical constructs of cognition. In order to minimize 
measurement error, an a priori outcome selection strategy similar to that used by previous 
meta-analytic studies (Ilieva et al., 2015) was used whereby instruments and measures 
were limited based on reliability and validity and commonality across studies (see Table 
1). The present meta-analysis focused on studies addressing the effects of prescription 
stimulants on the cognitive behaviors of processing speed accuracy, planning time, 
planning accuracy, advantageous decision-making, and cognitive perseveration because 
no meta-analyses have addressed these areas and because these areas proffer important 
implications for prescription stimulant misuse for academic enhancement. Specific 
instruments included: A) the Digit Symbol Substitution Task (DSST) to measure 
processing speed accuracy, B) the Iowa Gambling Task (IGT) to measure advantageous 
decision-making, C) the Tower of London Spatial Planning Task (TOL) and New Tower 
of London Spatial Planning Task (NTOL) to measure planning accuracy and time, and C) 
the Wisconsin Card Sorting Test (WCST) and the Intra-Extra Dimensional Set-shift Task 
(IDED) to measure cognitive perseveration. 
Processing Speed. Processing speed typically refers to the amount of time 
required to make an accurate judgment of a stimulus (Cella & Wykes, 2013; Owsley, 
2013). Completed with paper and pencil or on the computer, the Digit Symbol 
Substitution Task (DSST) measures attention, motor performance, response speed and 
visuomotor coordination (Silber, Croft, Papafotiou, & Stough, 2006) and on the Wechsler 
Adult Intelligence Scale – Fourth Edition (WAIS-IV), the DSST score is combined with 
the Symbol Search task score to generate a standard score of processing speed that 
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measures skills in speed of mental problem-solving, attention, and hand-eye coordination. 
The task provides a list of nine individually paired digits and symbols that participants 
use as a key to substitute numbers with symbols as efficiently as possible (Litchenberger 
& Kaufman, 2009). Although a number of additional measures of processing speed are 
available in the literature (e.g., continuous performance tests, trail making tasks, and 
reaction time), these tasks rely on a wide range of dimensions of performance. To 
minimize heterogeneity in cognitive processes, and because the DSST is used widely in 
the literature as a control measure of processing speed, accuracy measures of the DSST 
were selected to measure processing speed. Accuracy measures included number of trials 
correct in a specified amount of time (accuracy - total) or proportion of correct trials out 
of total trials attempted in a specified amount of time (accuracy - proportion).  
Planning and Decision-Making. Among other capacities, planning and decision-
making require looking ahead, objective assessments, perceiving alternatives, weighing 
choices, and utilizing conceptual frameworks (Lezak et al., 2012). Memory, impulse 
control, and sustained attention are all necessary components of planning and decision-
making behavior. Tests of planning may include gambling tasks and test of decision-
making may include tower tests (Lezak et al., 2012). 
Although a number of iterations of gambling tasks are available, a commonly 
used task is the Iowa Gambling Task (IGT). The IGT is played with cards on a computer 
in which the participant selects varying decks and cards with the purpose of minimizing 
losses and winning as much money as possible (Lezak et al., 2012). The IGT presents 
four decks of cards of which half yield consistent large gains and larger losses and half 
yield consistent small gains and smaller losses (Agay et al., 2014). We prioritized number 
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of advantageous choices or probability of selecting most likely outcomes from the IGT to 
measure the tendency to choose advantageously within decision-making. Note that the 
number of disadvantageous choices was equal to the total number of choices minus the 
number of advantageous choices (i.e., when added together, they sum to the total number 
of opportunities); therefore, the number of disadvantageous choices was also used as a 
negative representation of advantageous choices. 
The Tower of London Spatial Planning Task (TOL) and the New Tower of 
London Spatial Planning Task (NTOL) are the most commonly used versions of the 
tower tasks. These tasks require participants to rearrange rings or balls of varying colors 
to arrive at the solution using the least number of moves and in the most direct way 
(Lezak et al., 2012). The TOL requires participants to physically move the balls or discs 
to come to the most efficient solution. The NTOL also requires participants to work out 
the most efficient solution; however participants do not physically arrange the balls/discs 
as they do in the TOL (Elliott et al., 1997). Both planning accuracy and planning time 
were selected as measures of planning from the TOL and NTOL.  
Cognitive Perseveration.  Tasks of cognitive flexibility and the capacity to shift 
require respondents to shift their thinking by changing the rules during the task (Lezak et 
al., 2012). The Wisconsin Card Sorting Test (WCST) and the Intra-Extra Dimensional 
Set-shift Task (IDED) are common tests of cognitive flexibility with performance 
outcomes that measure cognitive perseveration (Lezak et al., 2012; Wild & Musser, 
2014). The WCST is used to assess abstract concepts and set-shifting (Spreen & Strauss, 
1998) by requiring participants to deduce a pattern by matching cards of varying symbols 
and shapes based on the examiner’s cues (Lezak et al., 2012). An analog to the WCST, 
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Cambridge Neuropsychological Test Automated Battery’s (CANTAB) IDED set shifting 
test involves visual discrimination and attentional set formation (Barker, Pope, Smith, 
Brown, & Hall, 2014; Wild & Musser, 2014). Participants view two color-filled shapes 
and must learn through trial and error based on computer driven feedback which response 
is correct (Cambridge Cognition, 2015). The test becomes increasingly difficult as it 
progresses through nine stages, transitioning from intra-dimensional to extra-dimensional 
rules (Wild & Musser, 2014). We focused on perseveration as a measure of flexibility, 
prioritizing the selection of perseverative errors and Extra-dimensional reversal shift 
errors from the WCST and IDED, respectively. 
Statistical Methods 
Meta-analyses, which pool weighted estimates of effects into a common metric 
across studies (Aloe, 2014; Lipsey & Wilson, 2001), were conducted on the retrieved 
studies using the program Biostat’s Comprehensive Meta-analysis (www.meta-
analysis.com) (Borenstein, Hedges, Higgins, & Rothstein, 2015). In total, 15 individual 
meta-analyses were conducted that included five measures of cognition across three types 
of medication dose (averaged, low, and high medication doses). Because results were 
similar across meta-analyses conducted separately for high and low doses only the 
averaged medication dose findings are presented here (see Supplementary Tables S1a and 
S1b). Primary analyses included effect size calculation for maximum change in cognition 
of treatment compared to control. Additional analyses included visual inspection of 
outliers, homogeneity tests of effect size distribution, analyses of publication bias, and 
exploration of potential moderating variables. 
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Assessment of Effect Size. Effect sizes measuring post-treatment differences 
between placebo and control groups were calculated from a variety of statistics, including 
descriptive data, i.e., means and standard deviations, and inferential statistics, i.e., F (in 
cases of df = 1) and t. For missing raw data necessary for effect size computation, a 
request for more information was made to researchers; otherwise, studies with missing 
data for effect size computation were excluded.  Effect sizes were combined from studies 
that used both parallel and crossover designs. The appropriateness of synthesizing effect 
size data across parallel and crossover designs has been largely debated in the 
methodological literature (e.g., Elbourne et al., 2002; Lipsey & Wilson, 2001). Results 
from studies using crossover designs may be biased from carryover effects where the 
initial intervention effects may influence responses on subsequent interventions 
(Elbourne et al., 2002). In order to identify heterogeneity between study designs, the 
present study selected study design a priori as a moderator of interest. 
Results were converted to the standardized mean difference (Hedge’s g) for 
comparing across studies. The formulas for calculating Hedge’s g vary according to study 
design and available data. In general, however, the formula for Hedge’s g is calculated by 
taking d, which is the difference of group means divided by the pooled within group 
standard deviation (Borenstein, Hedges, Higgins, & Rothstein, 2009; Hedges, 1981; 
Lipsey & Wilson, 2001), then multiplying by the coefficient J, a correction factor to 
account for small sample bias (Borenstein et al., 2009). Considering most of the included 
studies used a within-subjects or crossover design, it is important to note that the 
calculation of effect sizes from these studies require a different set of formulas than 
between-subjects or parallel designs. While between-subjects studies’ natural unit of 
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deviation is the standard deviation within groups, the standard deviation of the difference 
score (SDDIFF) is the statistic of interest for estimating the natural unit of deviation for 
within-subjects studies (Borenstein et al., 2009). The particular equations used to 
calculate Hedge’s g for between-subjects or parallel designs and within-subjects or 
crossover designs can be accessed in the Appendix (see Supplementary Tables S2a and 
S2b). 
Assumption of Independence. Meta-analysis relies on the assumption that each 
measure of effect is representative of independent studies. Most studies investigating 
prescription stimulant effects reported findings from multiple outcomes, however, 
yielding a potential for multiple effect size estimates. Therefore, a protocol to handle 
studies with more than one effect size was used and guidelines can be found in the 
appendix (Supplementary Table S3). 
Meta-analytic Technique. A random effects model, which assumes that 
measured effect sizes are subject to sampling error and random effects variance (Lipsey 
& Wilson, 2001), was chosen a priori given the heterogeneity of the design of studies 
and cognitive measures as recommended by Field and Gillett (2010) and Hunter and 
Schmidt (2000).  
Homogeneity of the effect size distribution was tested visually, with forest plots, 
and statistically, with the use of the Q statistic and I
2 
(95% CI) index. The Q statistic is a 
standardized measure that approximates to a chi-square distribution with k – 1 degrees of 
freedom, where k is the number of studies (Hedges & Olkin, 1984; Huedo-Medina, 
Sánchez-Meca, Marín-Martínez, & Botella, 2006). A statistically significant Q is 
indicative of a heterogeneous distribution, signaling the potential to test for moderators 
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(Lipsey & Wilson, 2001). The I
2
 statistic is an index between 0 and 100% and is used as 
an estimate for the amount of statistical impact of heterogeneity on the total observed 
variation (Borenstein et al., 2009). Higgins, Thompson, Deeks, and Altman (2003) have 
suggested heterogeneity can be interpreted as low (I
2
 = 25%), moderate (I
2
 = 50%), or 
high (I
2
 = 75%). 
In order to verify accurate data entry and to account for potential effects of 
context within studies, a careful examination of any study level effect size outliers was 
conducted. In the case where outliers were identified because of large sample sizes, 
parallel analyses that included and excluded these outliers were conducted. To maintain 
as much data as possible, only extreme outliers (falling more than 3 standard deviations 
away from the mean) that were identified as irrelevant or out of context were removed 
from the final analysis (see Supplementary Tables S4a, S4b, S4c, and S4d). Note that for 
the present study, a decision to retain all studies in the subsequent analyses was made 
considering their minimal effects on mean effect sizes. 
While efforts were made to request descriptive and/or inferential data for every 
eligible study that was missing the necessary data to calculate measures of effects, studies 
in which data were not available for effect size calculations were excluded from the final 
analysis. Case analysis for studies that did report moderator data was employed. A 
decision to omit data, as opposed to imputing data, was made given the limited number of 
studies examining prescription stimulant effects in the selected areas of cognition.  
 Finally, six different methods were used to assess level and presence of 
publication bias: Egger’s regression index, the funnel plot, Duval and Tweedie’s trim and 
fill, Rosenthal’s fail-safe N, Orwin’s adapted version of Rosenthal’s fail-safe N, and an 
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assessment of publication bias (inclusion of non-behavioral measure) as a moderating 
variable.  
Statistical Tests of Moderators. Statistical tests of moderators were conducted 
for variables identified a priori as described previously, as well as any of the additional 
variables yielding a significant Q statistic. Because the moderating variables of interest 
were both categorical (type of drug, ADHD status) and continuous (dose, timing of dose, 
baseline functioning), analog to analysis of variance (ANOVA) and weighted regression 
analysis (meta-regression) using mixed effects models were run for tests of moderators.  
Results 
Search results 
 A total of 1,296 titles were initially identified via the bibliographic databases 
PsycINFO (257) and Pubmed (1039), including journal articles and book chapters (1273) 
and dissertations (23). A total of 21 studies met eligibility criteria of which 16 studies had 
sufficient data to calculate effect sizes met and were included in this study (see Table 2). 
Of these, 8 studies with a total of 345 participants examined prescription stimulant effects 
on processing speed, 5 studies with a total of 152 participants examined prescription 
stimulant effects on planning and decision-making, and 6 studies with a total of 337 
participants examined cognitive perseveration. A total of 10 studies examined the effects 
of AMP and 6 studies examined the effects of MPH. Note that while eligibility criteria 
allowed for both short-acting and long-acting agents, all of the included studies examined 
short-acting agents. 
Stimulant effects on processing speed accuracy 
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Data were extracted from 8 studies that investigated the neurocognitive effects of 
prescription stimulant medication on processing speed using a crossover design, resulting 
in a total of 345 participants (see Figure 1).  When all doses were averaged together, 
under the random effects model, the studies generated a statistically significant mean 
effect size of g =0.282 (95% CI 0.077, 0.488, p = .007), with effect sizes ranging between 
g = −0.061 to g = 0.645. The heterogeneity of variance analysis was significant, Q (7) = 
73.276 [I
2
 = 90.447], p <.001, indicating significant between-study variance.  
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 218 to 
lead to a p-value at or above an alpha of .05 and an Orwin’s N of 22 to reduce the 
measure of effect to 0.10. Under the random effects model, trim and fill analysis 
suggested the imputation of 4 studies to reduce negative bias resulting in an increased 
effect size of g = 0.518 (95% CI 0.310, 0.726)  (see Supplementary Figure 1) and Egger’s 
regression was significant [B = −5.305, SE = 1.918, t(6) = 2.766, 95% CI −9.998, 0.612, 
p = .032]. Five studies were excluded from the analysis because they did not have 
sufficient data to calculate effect sizes. Findings from these studies were mixed; three 
studies reported null findings (Crabbe et al., 1983; Holdstock & de Wit, 2001; Kennedy, 
Odenheimer, Baltzley, Dunlap, & Wood, 1990), one study reported positive findings 
(Hamidovic, Dlugos, Palmer, & de Wit, 2010), and the final study reported negative 
findings (i.e.,  MPH was associated with a reduction in processing speed accuracy; 
Kollins, Rush, Pazzaglia, & Ali, 1998). These findings suggest minimal risk of positive 
publication bias within analyses examining processing speed. 
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The significant Q statistic indicated between study variance so moderator analyses 
were conducted. None of the moderators demonstrated significant differences through 
metaregression or ANOVA analog.  
Stimulant effects on planning time, planning accuracy, and advantageous decision-
making 
Stimulant effects on tendency to choose advantageously. Data were extracted 
from 2 studies that investigated the neurocognitive effects of prescription stimulant 
medication on tendency to choose advantageously, resulting in a total of 44 participants 
(see Figure 2). When all doses were averaged together, under the random effects model, 
the studies generated a mean effect size of g = −0.191 (95% CI −0.561, 0.180, p = .313). 
The heterogeneity of variance analysis was not significant, Q (1) = 0.204 [I
2
 = 0.000], p 
=.656, indicating minimal between-study variance. ANOVA analog did not reveal 
significant differences between the study using a parallel design (g = -.045; Agay et al., 
2010) and the study using a crossover design (g = -0.241; Agay et al., 2014), Q(1) = 
0.204, p = .652. Given the effect size for tendency to choose advantageously was not 
statistically significant and the small number of studies included in the analysis, analysis 
of publication bias and moderator analyses were not conducted.  
Stimulant effects on planning accuracy. Data were extracted from 2 studies that 
investigated the neurocognitive effects of prescription stimulant medication on planning 
accuracy, resulting in a total of 79 participants (see Figure 3). When all doses were 
averaged together, under the random effects model, the studies generated a mean effect 
size of g =0.048 (95% CI -0.194, 0.290), p = .698) that was not statistically significant, 
with effect sizes ranging from g = 0.024 to g = 0.146. The heterogeneity of variance 
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analysis was not significant, Q (1) = 0.150 [I
2
 = 0.000], p =.698, indicating minimal 
between-study variance. ANOVA analog did not reveal significant differences between 
effect sizes from the study using a parallel design (g = 0.146; Turner et al., 2003) and the 
study using a crossover design (g = 0.024; Linssen et al., 2012), Q(1) = 0.150, p = .698. 
Publication bias and further moderator analyses were not conducted due to the small 
number of studies and minimal between-study variance. 
Stimulant effects on planning time. Data were extracted from 3 studies that 
investigated the neurocognitive effects of prescription stimulant medication on planning 
time, resulting in a total of 107 participants (see Figure 4). When all doses were averaged 
together, under the random effects model, the studies generated a mean effect size of g = 
−0.140 (95% CI −0.383, 0.102, p = .257) that was not statistically significant, with effect 
sizes ranging from g = -0.561 to g = 0.006. The heterogeneity of variance analysis was 
not significant, Q (2) = 3.452 [I
2
 = 42.062], p =.178.  
Given the effect size for planning time was not statistically significant, analysis of 
publication bias with Rosenthal’s N and Orwin’s N was not conducted. Trim and fill 
analysis indicated the imputation of 2 studies to reduce negative bias resulting in an 
effect size approaching 0, g = 0.006 (95% CI −0.237, 0.248) (see Supplementary Figure 
2). Egger’s regression was not significant [B = -3.386, SE = 1.020, t(1) = 3.319, 95% CI 
−16.350, 9.578, p = .186]. These findings suggest minimal risk of publication bias within 
analyses examining planning and decision time. ANOVA analog examining differences 
between effect sizes from the study using a parallel design (g = -0.561; Turner et al., 
2003) and the two studies using a crossover design (g = -0.060; Elliott et al., 1997; 
Linssen et al., 2012) was not significant, Q(1) = 2.808, p = .094. Given the small number 
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of studies available for analyses and the minimal heterogeneity between studies, 
additional moderator analyses were not conducted.  
Stimulant effects on cognitive perseveration 
Data were extracted from 6 studies that investigated the neurocognitive effects of 
prescription stimulants on perseveration, resulting in a total of 337 participants (see 
Figure 5). When all doses were averaged together, under the random effects model, the 
studies generated a mean effect size of g =0.003 (95% CI −0.095, 0.101), p = .949) that 
was not statistically significant, with effect sizes ranging from g = −0.138 to g = 0.254. 
The heterogeneity of variance analysis was not significant, Q (5) = 2.866 [I
2
 = 0], p = 
.721.  
Given the effect size for cognitive perseveration was not statistically significant, 
analysis of publication bias with Rosenthal’s N and Orwin’s N was not conducted. Trim 
and fill analysis indicated the imputation of 3 studies to reduce negative bias resulting in 
a negative effect size of g = −0.021 (95% CI −0.114, 0.072) (see Supplementary Figure 
3). Egger’s regression was not significant [B = 0.684, SE = 0.495, t(4) = 1.381, 95% CI 
−0.691, 2.060, p = .239]. These findings suggest minimal risk of publication bias within 
analyses examining cognitive perseveration. ANOVA analog did not reveal significant 
differences between effect sizes based on study design, Q(1) = 1.206, p = .272, in which 
two studies used a parallel design (g =  0.236) and four studies used a crossover design (g 
= -0.010). The overall Q statistic was not significant, indicating minimal between study 
variance so additional moderator analyses were not conducted.  
Discussion 
NEUROCOGNITIVE ENHANCEMENT OR IMPAIRMENT? 25 
The primary indications for ADHD prescription stimulant medication (e.g., 
Adderall, Ritalin, Dexedrine) are for the reduction of ADHD symptoms including 
impulsivity, hyperactivity, inattention. A, n increasing number of college students and 
non-student adults  with and without ADHD, however, have reported misusing these 
medications to enhance their academic functioning or productivity. Previous research 
examining the effects of prescription stimulant medication on cognition has typically 
relied on small sample sizes and yielded mixed results. Therefore, the present study 
conducted 15 meta-analyses to explore the potential for prescription stimulant medication 
as a neurocognitive enhancer, as well as influencing factors associated with its 
neurocognitive effects.  
Consistent with our primary hypothesis, prescription stimulant medication 
showed consistent and positive effects for increasing processing accuracy (g = 0.282). 
Study results for processing speed did not differ by dose level or across samples of 
varying ages or gender distributions.  This finding is consistent with previous meta-
analytic study findings that these medications have small and significant effects on other 
abilities of focused attention. Specifically, benefits from prescription stimulants in the 
areas of working memory (g = 0.13), inhibitory control (g = 0.20) (Illieva et al., 2015), 
and measures of vigilance (Riccio et al.,2001) have been reported in the literature.  
Previous researchers have questioned if prescription stimulants are associated 
with impairments of other components of cognition such as cognitive flexibility or 
perseveration (Advokat, 2010; Smith & Farah, 2011; Weyandt et al., 2013). Contrary to 
our hypothesis, the present study did not support the association of prescription 
stimulants with impairments in the area of cognitive perseveration (g = 0.003). Results 
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also revealed non-significant effects for tendency to choose advantageously (g = −0.191), 
planning accuracy (g = 0.048), and planning time (g = −0.140). It is important to note, 
however, that the small number of studies investigating these outcomes limit the 
interpretation of these findings. Indeed, the analysis examining the effects of MPH relied 
on a combined sample size of n = 44 among only 2 studies and resulted in a small 
negative effect size. One of these studies (Agay, 2014) also reported that participants 
with low performance at baseline tended to improve and those with high performance 
tended to demonstrate impairments. Unfortunately, due to the limited number of studies 
examining the effects of prescription stimulants on planning time, planning accuracy, and 
advantageous decision-making, analyses exploring moderator variables were not 
conducted in the present study. Thus, adequately powered studies that also take into 
accounts individual differences are needed to fully understand if prescription stimulants 
truly cause impairments to decision-making. 
Implications 
Even with findings supporting significant effects of prescription stimulant 
medication on processing speed accuracy, the question remains as to how meaningful 
these effects are in settings outside of the laboratory. In particular, are these effects 
meaningful for college students engaging in illicit stimulant misuse for academic 
purposes and non-student adults misusing stimulants for productivity? The included 
studies conducted cognitive assessments in research laboratories, providing an 
environment quite unlike one in which college students and other adults would normally 
work, study, read or write. In fact, research accumulated over the past three decades has 
suggested prescription stimulant medication results in minimal to no effects on the 
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overall academic achievement in children with ADHD, even though it may increase 
attention and improve productivity, (Advokat, 2010; Lakhan & Kirchgessner, 2012). 
Studies that directly investigate the neurocognitive effects of prescription stimulant 
medication on academic tasks and work productivity will help shed light on how 
meaningful the effects found in the present study are regarding prescription stimulant 
misuse.  
Another important consideration is the wide range of medication doses included 
in the present study that may not reflect the levels of medication college students and 
other adults are misusing. The literature on prescription stimulant misuse does not 
provide an indication of the typical dose being misused; however, medication is most 
effective when titrated according to individual assessment (Coghill et al., 2013) and some 
individuals appear to perform better with lower doses compared to higher ones. If varying 
doses also result in cognitive impairments (or worse, adverse health outcomes), college 
students and other adults would benefit from safety information and efficacy information 
regarding prescription stimulant medication dose. Future studies investigating 
prescription stimulant effects on tasks involving actual academic assignments (e.g., essay 
composition, calculus problems) or work productivity, comparing doses optimal for 
behavior improvement to lower doses in adult populations would shed light on this issue 
(Weyandt et al, 2013; Weyandt et al., 2014). 
Of note, there are a number of interventions being explored for their potential as 
cognitive neuroenhancers for processing speed that could serve as an alternative to 
prescription stimulant medication, including video games (between d = 0.48 to d = 1.47; 
Dye, Green, & Bavelier, 2009), and exercise (d = 0.091;Chang, Labban, Gapin, & Etnier, 
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2012). Although the present study’s findings revealed smaller effect sizes from 
prescription stimulant medication for processing speed enhancement than the previously 
described video game interventions, the ease of taking a medication compared to long-
term trainings and programs should not be overlooked. Even a small boost in 
enhancement may be meaningful when applied to an increase in a grade for college 
students (Ilieva et al., 2015), especially considering it can result in near immediate 
effects. 
Methodological Considerations 
The present study has a number of strengths that support its contribution towards 
uncovering the potential of prescription stimulant medication as a neurocognitive 
enhancer. Studies were searched for and retrieved from multiple bibliographic databases 
in order to capture as much data as possible and minimize publication bias. This study 
was the first meta-analysis to explore the effects of prescription stimulant medication on 
cognitive perseveration, planning and decision-making. Importantly, a major strength of 
the present study involved the well-established methodology applied to calculate mean 
effect sizes and test for moderator variables. It is particularly important to emphasize that 
previous studies examining the neurocognitive effects of prescription stimulant 
medication have relied on sample sizes that were likely underpowered. Indeed, the 16 
studies included in the present study relied on small sample sizes (mean n = 35) and 
resulted in small effect sizes. Therefore, this meta-analytic study, which pooled weighted 
estimates of effects and resulted in more power than individual studies, contributes 
substantially to the literature. 
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A number of limitations are also important to note, however, relating to the 
study’s design and methodology and studies investigating the cognitive effects of 
prescription stimulant medication in general. First, a limitation concerning meta-analysis 
methodology concerns its potential to overlook important individual variation by 
focusing on between-study variance (Egger & Smith, 1998). For example, the inclusion 
of one study (Turner et al., 2003) that focused on healthy elderly males may represent 
findings relevant only to elderly populations and limits the generalizability of this study. 
Additionally, meta-analysis is plagued by issues of limited power for moderator variable 
detection (Hedges & Pigott, 2004). The absence of significant moderator variables in the 
present study may reflect a lack of power as opposed to lack of variability.  
 A related issue that is often raised regarding meta-analyses is the potential 
influence of publication bias on meta-analytic findings.  Because methods to measure and 
minimize publication bias may require a larger number of studies than included in the 
present study, we utilized a wide range of techniques (Egger’s regression index, the 
funnel plot, Duval and Tweedie’s trim and fill, Orwin’s adapted version of Rosenthal’s 
fail-safe N, and an assessment of publication bias as a moderating variable) to account for 
this limitation. Findings from publication bias analyses suggested that in general the 
included studies tended towards negative bias. In other words, the present study may 
have overrepresented smaller and more negative effects in the literature as opposed to 
larger and positive effects, which are typically associated with publication bias. Still, a 
concern regarding the exclusion of missing data should be noted.  
 Previous meta-analyses examining the efficacy of prescription stimulant 
medication for improvements in ADHD symptoms have found significant differences 
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between studies using change scores, i.e. studies comparing baseline scores, and post-
treatment (or endpoint scores), i.e. studies comparing changes between placebo and 
medication scores, as measurement outcome (Faraone et al., 2006). Because all of the 
studies included in the present study reported data to calculate endpoint scores, findings 
in the present study were based on differences between placebo and medication scores.  
 Another important consideration is the susceptibility of meta-analysis to overlook 
important influences, such as the social context of the study, the quality of the study, and 
theoretical influences/implications (Lispey & Wilson, 2001). For example, in their meta-
analysis assessing stimulant effects on ADHD symptomatology, Faraone & Glatt (2010) 
suggested that the systematic variability across methodology between classes of drugs 
may have produced misleading results. On the other hand, two recent reviews exploring 
the cognitive effects of prescription stimulant medication in children (Pietrzak, Mollica, 
Maruff, & Snyder, 2006) and in adults (Linssen et al., 2014) suggested that the use of 
meta-analysis for these investigations would be inappropriate due to the variability across 
study methodology, participant characteristics, treatment conditions and 
neuropsychological instruments used across studies. In order to account for variability, 
the present study only included studies meeting more rigid criteria (e.g., specific 
measures only). 
Finally, although meta-analysis is a powerful method that may help uncover the 
true effect of an intervention (Kraemer, Gardner, Brooks, & Yesavage, 1998), results are 
limited by the quality of available published studies. Many criticisms of meta-analysis 
stem from the decision to either maintain open inclusion criteria (leading to a variety of 
studies that may not be comparable) or to adopt rigid inclusion criteria (resulting in less 
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meaningful findings because of the exclusion of potentially meaningful studies) (Kraemer 
et al., 1998). Although the present study used specific inclusion criteria to select studies 
meeting standards of quality, a wide variety of study designs and study methodology 
were included. It is important to note that study design was selected a priori as a 
moderator variable and differences in effect sizes across parallel and crossover studies 
were not found; however, the small number of included studies also limited these 
analyses.  
Finally, a critically important limitation in this literature was the omission of 
reporting participant ethnicity across most studies. It is unclear why so few studies 
investigating the cognitive effects of prescription stimulant medication reported 
participant ethnicity, but it will be important for future research to include more 
ethnically diverse populations.  
Future Research  
The present findings suggest that prescription stimulant medication may act as a 
neurocognitive enhancer of processing speed without impeding other domains of 
cognition such as flexibility. These effects, although small, appear to be significant for 
adults of varying ages and may be comparable for men and women. Still, a number of 
questions remain unanswered about the effects of prescription stimulant medication for 
cognition among varying populations that may help elucidate their mechanism of action. 
Research is warranted to further investigate a number of areas related to 
prescription stimulant medication for cognitive enhancement. The potential for 
moderating effects of participant characteristics, particularly baseline cognitive 
functioning and related genotype variability, need to be clarified. If only adults with 
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lower baseline cognitive functioning scores or those homozygous to a particular genotype 
receive neurocognitive benefits from prescription stimulants many adults misusing 
prescription stimulants are taking unnecessary risks with minimal results. Or worse, if 
prescription stimulant medication actually impairs cognitive functioning in certain 
individuals, some adults may actually be worsening their ability to engage in higher-level 
learning.  
Although the present study’s findings are clinically and empirically important, 
limitations related to the external validity of the included measures limit the finding’s 
generalizability to populations in academic settings. More specifically, research 
examining representative populations of college students will directly inform the 
potential enhancement or impairments associated with prescription stimulant misuse 
during late adolescence and early adulthood.  Considering the neurodevelopmental 
changes that occur during late adolescence and early adulthood, findings from the present 
study that included adults across a range of ages may not adequately represent the manner 
in which prescription stimulant misuse impacts cognition in college aged populations. 
The present study addressed cognitive constructs not previously studied, but 
additional areas of cognition should also be investigated in relation to prescription 
stimulant medication. For example, prescription stimulant medication may offer greater 
benefits for other areas of cognition, such as volition and motivation, the latter of which 
has been suggested to be a mechanism of prescription stimulants for neuroenhancement 
(Volkow et al., 2008). Additional measures of processing speed (e.g., continuous 
performance tasks, response time for item recognition tasks) should also be examined to 
validate the present study’s findings that prescription stimulants may proffer benefits for 
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processing speed accuracy. Furthermore, the finding that prescription stimulant 
medication did not result in effect sizes significantly different than zero on tasks of 
planning time and accuracy, advantageous decision-making, and cognitive perseveration 
was based on a small number of studies, requiring further examination.  
Finally, further research is warranted to better understand the underlying 
statistical power of studies that have examined the effects of prescription stimulant 
medication on neurocognitive enhancement. Sample sizes of the studies included in the 
present investigation ranged from n = 6 to n = 192; however, the vast majority of studies 
(k = 11, 68.75%) relied on sample sizes that included less than 30 participants. 
Considering the consistently small effect sizes found in the present study, it is likely that 
these and previous studies examining cognition and prescription stimulant medication 
have been greatly underpowered. Given this serious limitation in the literature, future 
studies should reference findings from existing meta-analyses as guides when 
determining required sample sizes. 
Future Directions 
A number of ethical and social issues related to prescription stimulant medication 
as a neurocognitive enhancer have garnered attention in the literature (e.g., Dubljević, 
2013; Farah, 2004; Goodman, 2010). Critics of cognitive neuroenhancers have compared 
cognitive neuroenhancement to cheating, arguing that gains made under 
neuroenhancement cannot be claimed as the user’s own (Goodman, 2010). However, a 
recent survey of German students revealed only small correlations between the use of 
cognitive neuroenhancers and the acts of plagiarism and fabrication (Dubljević, Sattler, & 
Racine, 2014), suggesting users may not necessarily perceive cognitive 
NEUROCOGNITIVE ENHANCEMENT OR IMPAIRMENT? 34 
neuroenhancement to be as unethical as acts generally considered to be cheating. 
Arguments about the equivalence of cognitive neuroenhancement to academic dishonesty 
are analogous to debates about the use of anabolic steroids and human growth hormone 
performance among professional athletes – that are now generally considered to be illegal 
in most professional sports leagues. Yet, pharmacological enhancement is not unique to 
the area of cognition as it is already being used to control mood, sleep, appetite and sex 
(Farah, 2004; Farah et al., 2004).  
The present study’s findings, in conjunction with previous research, indicate that 
prescription stimulant medication provides small, but significant cognitive effects across 
multiple domains of cognition, i.e., cognitive neuroenhancement. Irrespective of peoples' 
ethical and professional views on the issue, prescription stimulants are being used 
illegally for the purpose of cognitive neuroenhancement and at high rates across many 
college campuses. Therefore, the establishment of public policies surrounding this issue, 
whether restrictive or liberal, is of critical importance. An important policy consideration 
concerns the abuse potential of prescription stimulants among healthy college students 
and non-student adults. Evidence supports that both AMP and MPH hold a high abuse 
potential for physiological and/or psychological dependence, but instances of abuse 
among ADHD populations are actually rare (Kollins, 2007). To date, the literature on 
prescription stimulant misuse has largely focused on prevalence rates and adult 
characteristics associated with misuse. Research examining the potential for 
psychological and physical abuse of these drugs among healthy adults is sorely needed to 
inform the development of public policy concerning this issue. As Farah and colleagues 
(2004) aptly explained, “The question is therefore not whether we need policies to govern 
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neurocognitive enhancement, but rather what kind of policies we need” (p. 424). The 
answer to this question needs to be informed by collaborative efforts across the sciences. 
The interdisciplinary nature of this public policy issue is clear, as cognitive effects and 
potential for abuse from prescription stimulants likely depend on the interplay of 
individual characteristics (i.e., genetic variability), pharmacological mechanisms and 
actions, and cognitive effects encompassing behavioral science and behavioral 
neuroscience. 
Conclusion 
The present study supports the effectiveness of prescription stimulant medication 
for neurocognitive enhancement of processing speed accuracy in the adult population. 
While preliminary findings also indicate prescription stimulant medication does not 
appear to impair nor enhance planning, decision-making or cognitive perseveration, it is 
important to note that only a small number of studies addressed these outcomes. The 
present findings suggest that college students misusing prescription stimulants for 
academics and non-student adults misusing prescription stimulants for productivity may 
actually receive meaningful benefits. Further research is warranted, however, to 
investigate whether enhancement of tasks of cognition translate to boosts in academic 
grades in the college setting or increased productivity in the workplace. Public policy 
informed by collaborations across the sciences that addresses the use of prescription 
stimulant medication for neurocognitive enhancement is needed given the 
interdisciplinary nature of this topic.  
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Figure Legends 
 
Figure 1. Overview of meta-analysis of processing speed accuracy. Eight studies 
examining effects of amphetamine on processing speed accuracy; Summary Cohen’s d 
calculated with random effects model. 
 
Figure 2. Overview of meta-analysis of tendency to choose advantageously. Two studies 
examining effects of methylphenidate effects on tendency to choose advantageously; 
Summary Cohen’s d calculated with random effects model. 
 
Figure 3. Overview of meta-analysis of planning accuracy. Two studies examining 
effects of methylphenidate effects on planning accuracy; Summary Cohen’s d calculated 
with random effects model. 
 
Figure 4. Overview of meta-analysis of planning time. Two studies examining effects of 
methylphenidate effects on planning time; Summary Cohen’s d calculated with random 
effects model; RT = response time. 
 
Figure 5. Overview of meta-analysis of cognitive perseveration. Six studies examining 
effects of amphetamine and methylphenidate effects on cognitive perseveration; 
Summary Cohen’s d calculated with random effects model; ED = Extra dimensional. 
 
